A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingA Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma

A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingA PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)

Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingPhase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma

Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingStem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors

Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingPhase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingAutologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingTACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

• Post author:
• Post published:May 12, 2025
• Post category:

Continue ReadingA Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS

• Post author:
• Post published:May 12, 2025
• Post category:

BioEclipse combines two approaches - an immune cell called a cytokine-induced killer (CIK) cell and a virus engineered to kill cancer cells called an oncolytic virus (OV) - to create…

Continue ReadingPHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS

Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma

• Post author:
• Post published:May 12, 2025
• Post category:

Crystal Mackall, M.D., and her team at Stanford University will modify a patient's own T cells, an immune system cell that can destroy foreign or abnormal cells.  The T cells…

Continue ReadingPhase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma